IDEXX Laboratories vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

IDEXX Laboratories Inc (IDXX)

Q3 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

August 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Latest21 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.